IL299750A - Lipid nanoparticles for the delivery of therapeutic agents to the lungs - Google Patents

Lipid nanoparticles for the delivery of therapeutic agents to the lungs

Info

Publication number
IL299750A
IL299750A IL299750A IL29975023A IL299750A IL 299750 A IL299750 A IL 299750A IL 299750 A IL299750 A IL 299750A IL 29975023 A IL29975023 A IL 29975023A IL 299750 A IL299750 A IL 299750A
Authority
IL
Israel
Prior art keywords
lungs
lipid nanoparticles
delivering therapeutics
therapeutics
delivering
Prior art date
Application number
IL299750A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of IL299750A publication Critical patent/IL299750A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL299750A 2020-07-10 2021-07-08 Lipid nanoparticles for the delivery of therapeutic agents to the lungs IL299750A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050594P 2020-07-10 2020-07-10
PCT/US2021/040913 WO2022011156A1 (en) 2020-07-10 2021-07-08 Lipid nanoparticles for delivering therapeutics to lungs

Publications (1)

Publication Number Publication Date
IL299750A true IL299750A (en) 2023-03-01

Family

ID=79552114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299750A IL299750A (en) 2020-07-10 2021-07-08 Lipid nanoparticles for the delivery of therapeutic agents to the lungs

Country Status (10)

Country Link
US (1) US20240065982A1 (https=)
EP (1) EP4178585A4 (https=)
JP (1) JP2023534206A (https=)
KR (1) KR20230038217A (https=)
CN (1) CN115768438A (https=)
AU (1) AU2021305214A1 (https=)
CA (1) CA3188661A1 (https=)
IL (1) IL299750A (https=)
MX (1) MX2023000511A (https=)
WO (1) WO2022011156A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019376006A1 (en) 2018-11-09 2021-06-03 Arbutus Biopharma Corporation Cationic lipids containing silicon
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023184038A1 (en) 2022-04-01 2023-10-05 Nanovation Therapeutics Inc. Mrna delivery method and composition thereof
JP2025535237A (ja) * 2022-10-25 2025-10-24 ナノベーション・セラピューティクス・インコーポレイテッド アンチセンスオリゴヌクレオチド送達のための脂質ナノ粒子製剤
WO2025133951A1 (en) * 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2025166325A1 (en) 2024-02-02 2025-08-07 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
CN118576568B (zh) * 2024-08-06 2024-11-26 北京悦康科创医药科技股份有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721333C (en) * 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
US20180200186A1 (en) * 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
CA3103528A1 (en) * 2018-06-19 2019-12-26 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mrna and long nucleic acids
DE102018127300A1 (de) * 2018-10-31 2020-04-30 Henkel Ag & Co. Kgaa Wirkstoffzusammensetzung zum Schutz künstlich gefärbter Haare
AU2019376006A1 (en) * 2018-11-09 2021-06-03 Arbutus Biopharma Corporation Cationic lipids containing silicon
EP3959314A4 (en) * 2019-04-26 2023-02-08 Genevant Sciences Gmbh LIPIDNANOPARTICLES

Also Published As

Publication number Publication date
EP4178585A1 (en) 2023-05-17
CN115768438A (zh) 2023-03-07
US20240065982A1 (en) 2024-02-29
KR20230038217A (ko) 2023-03-17
WO2022011156A9 (en) 2022-03-17
CA3188661A1 (en) 2022-01-13
WO2022011156A1 (en) 2022-01-13
JP2023534206A (ja) 2023-08-08
EP4178585A4 (en) 2024-11-20
AU2021305214A1 (en) 2023-02-23
MX2023000511A (es) 2023-02-13

Similar Documents

Publication Publication Date Title
IL299750A (en) Lipid nanoparticles for the delivery of therapeutic agents to the lungs
PH12015500686A1 (en) Nicotine composition
DK3284459T3 (en) Pharmaceutical compositions comprising a local anaesthetic such as Bupivacaine for local administration to the mouth or throat
IL232762A0 (en) Aerosol device for inhalation of drugs that does not depend on the drug profile
MY167953A (en) Flavoured rods for use in aerosol-generating articles
PL3124015T3 (pl) Kompozycje i sposoby dostarczania miejscowego prostaglandyn do tłuszczu podskórnego
PH12014500551A1 (en) Pharmaceutical composition for inhalation
EP2544742A4 (en) APPARATUS AND METHOD FOR THE DELIVERY OF LUNG AEROSOL OR OTHER BODY LOCATIONS
EP2370068A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
WO2013163303A3 (en) Transferrin receptor aptamers and aptamer-targeted delivery
IL232970A0 (en) Oral spray compounds
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
PL2766008T3 (pl) Kompozycja do podawania donosowego o ulepszonej stabilności
EP2688628A4 (en) DISCHARGE OF DILUTED OXYGEN TO A PATIENT
IL227666A0 (en) Aclidinium for use in improving the quality of sleep in respiratory patients
PL3369429T3 (pl) Kompozycja farmaceutyczna przeznaczona do podawania na błonę śluzową nosa
HK40084784A (en) Lipid nanoparticles for delivering therapeutics to lungs
EP3065705A4 (en) Compositions and methods for administration of an enzyme to a subject's airway
ZA201308158B (en) Improved suspension formulation of a corticosteroid for administration by inhalation
GB201111226D0 (en) Improvements in relating to urological catheters
SG11201501020WA (en) Pharmaceutical composition for increasing content and availability of cyclic adenosine monophosphate in a body and the preparation thereof
MX2014011922A (es) Composicion para el tratamiento de desordenes inflamantorios e inmunes.
GB201216515D0 (en) Flavoured medicament associated with metered dose inhalers for the treatment of chronic inflammatory disorders
IN2013DE00880A (https=)
GB201005204D0 (en) Improvements in heterotypic formulations of anticancer drugs